| 1995 | Exact Sciences is founded |
| 2001 | Exact Sciences holds Initial Public Offering |
| 2004 | Oncotype DX Breast Recurrence Score® test launched |
| 2007 | Oncotype DX Breast Recurrence Score test included in the American Society of Clinical Oncology (ASCO® ) guidelines |
| 2008 | Oncotype DX Breast Recurrence Score test included in the U.S. National Comprehensive Cancer Network (NCCN®) guidelines |
| 2009 | Oncotype DX Breast Recurrence Score test helps more than 100,000 patients worldwide |
| 2010 | Oncotype DX Colon Recurrence Score™ test launched |
| 2011 |
Oncotype DX Breast DCIS Score™ test (ductal carcinoma in situ) launched Oncotype DX Breast Recurrence Score test recognised by St. Gallen expert consensus |
| 2013 |
Oncotype DX Genomic Prostate Score™ test launched Oncotype DX Breast Recurrence Score test recommended by the National Institute for Health and Care Excellence (NICE)* in England Oncotype DX breast cancer test included in the European Society for Medical Oncology (ESMO®) guidelines |
| 2014 |
The Oncotype DX® portfolio of tests helps more than 500,000 patients worldwide Cologuard®, the company's multi-target stool DNA, non-invasive colorectal cancer screening test approved by the U.S. Food and Drug Administration (FDA) The American Cancer Society (ACS®) guidelines include Cologuard in a recommended list of screening options for colorectal cancer |
| 2015 |
NHS patients in England gain access to the Oncotype DX Breast Recurrence Score test |
| 2016 |
Updated NICE quality standard recommends the Oncotype DX test in early-stage breast cancer |
| 2018 |
Landmark TAILORx primary results published in The New England Journal of Medicine, showing that the Oncotype DX Breast Recurrence Score test identifies the vast majority of women with node-negative disease who receive no substantial benefit from chemotherapy (approximately 80%), as well as the important minority for whom chemotherapy can be life-saving. |
| 2019 |
Exact Sciences and Genomic Health combine, creating leading global cancer diagnostics company The Oncotype DX portfolio of tests helps more than one million patients worldwide |
| 2020 |
Exact Sciences completes acquisition of Paradigm and Viomics, extending leadership in advanced cancer diagnostics |
*NICE © Diagnostics Guidance DG34, December 2018. www.nice.org.uk/guidance/dg34 (assessed Oct 2020). All rights reserved. Subject to Notice of rights NICE guidance is prepared for the National Health Service in England. All NICE guidance is subject to regular review and may be updated or withdrawn. NICE accepts no responsibility for the use of its content in this product/publication